eli lilly gip/glp-1 GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Lilly's GLP-1 pill outperforms Novo's

PsA Disease Activity Improves on GLP-1s A retrospective study presented at ACR Convergence 2025, led by researchers from the University of Toronto and NYU, followed 48 patients with psoriatic arthritis who started GLP-1 receptor agonists. The findings: Significant weight loss (35% of patients lost 510% of body weight

Utility of waist circumference percentile for risk evaluation in obese children

Different product types could also fare differently in this changing landscape

Communicate responsibly Educational content should avoid claims such as GLP-1 hair transplants or permanent correction of Ozempic hair loss. More credible messages include: Hair shedding during weight loss deserves a formal diagnosis

For treatment through the NHS, patients are typically required to have: A Body Mass Index (BMI) of 40 or above At least four of the following weight-related conditions High blood pressure (hypertension) Heart disease (cardiovascular disease) Abnormal blood fats (dyslipidemia) Obstructive sleep apnea Type 2 diabetes Must have tried other weight loss methods first Women make up the majority of Mounjaro users in the UK at more than three-quarters (77.6%), while men account for 22.4% of users

At TrimRx, our mission is to provide the clinical expertise and empathetic support you need to make these changes sustainable